NASDAQ:ADRO Aduro Biotech (ADRO) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free ADRO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$2.28▼$14.6052-Week Range N/AVolume171,500 shsAverage Volume162,237 shsMarket Capitalization$236.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aduro Biotech alerts: Email Address Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About Aduro Biotech Stock (NASDAQ:ADRO)Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.Read More Ad MarketBeatYour $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionStart Your Risk-Free Trial Here ADRO Stock News HeadlinesFebruary 24, 2024 | morningstar.comAduro Clean Technologies Inc Ordinary SharesJanuary 3, 2024 | morningstar.comPT Adaro Energy Indonesia TbkMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.December 2, 2023 | morningstar.comPT Adaro Energy Indonesia Tbk ADRONovember 16, 2023 | benzinga.comLegend Biotech Stock (NASDAQ:LEGN), Analyst Ratings, Price Targets, PredictionsNovember 10, 2023 | seekingalpha.comBret JensenNovember 6, 2023 | reuters.comConcord Biotech LtdJune 26, 2023 | thestreet.comAduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage StudyMarch 29, 2024 | Crypto Swap Profits (Ad)Grab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 18, 2023 | finance.yahoo.comFrench biotech Sensorion does not expect any impact to its liquidity from SVB's closureMarch 15, 2023 | reuters.comSVB shock could have chilling effect on British biotech sectorMarch 15, 2023 | cnbc.comSVB fallout: The impacts on the biotech sectorDecember 17, 2022 | thestreet.comCancer Immunotherapy Remains Hot as Aduro Biotech Doubles in Value On IPO DebutNovember 30, 2022 | finance.yahoo.comAduro Selected for Shell GameChanger ProgramOctober 29, 2022 | barrons.comMerck’s CFO Says Biotech Deals are Getting DoneSeptember 28, 2022 | finance.yahoo.comPT Adaro Energy Indonesia Tbk (ADRO.JK)July 31, 2021 | barrons.comAdaro EnergySee More Headlines Receive ADRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aduro Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/04/2020Today3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ADRO CUSIPN/A CIK1435049 Webwww.aduro.com Phone(206) 485-7051FaxN/AEmployees152Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,370,000.00 Net Margins-230.92% Pretax MarginN/A Return on Equity-101.73% Return on Assets-22.35% Debt Debt-to-Equity RatioN/A Current Ratio8.91 Quick Ratio8.91 Sales & Book Value Annual Sales$17.26 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / BookN/AMiscellaneous Outstanding Shares16,212,000Free FloatN/AMarket Cap$236.61 million OptionableOptionable Beta0.40 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesEric L. DobmeierChairman, President & Chief Executive OfficerAlan GlicklichChief Medical OfficerKirk D. SchumacherSenior Vice President & General CounselTom FrohlichChief Business OfficerNoopur LiffickVP-Investor Relations & Corporate CommunicationsKey Competitors23andMeNASDAQ:METrevi TherapeuticsNASDAQ:TRVIFibroGenNASDAQ:FGENXBiotechNASDAQ:XBITVerrica PharmaceuticalsNASDAQ:VRCAView All Competitors ADRO Stock Analysis - Frequently Asked Questions How were Aduro Biotech's earnings last quarter? Aduro Biotech, Inc. (NASDAQ:ADRO) announced its earnings results on Monday, May, 4th. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.05. The biotechnology company earned $13.95 million during the quarter, compared to the consensus estimate of $8.81 million. Aduro Biotech had a negative net margin of 230.92% and a negative trailing twelve-month return on equity of 101.73%. What other stocks do shareholders of Aduro Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aduro Biotech investors own include Regulus Therapeutics (RGLS), Exact Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Nabriva Therapeutics (NBRV), Amarin (AMRN), Anavex Life Sciences (AVXL), Micron Technology (MU), VBI Vaccines (VBIV) and PTC Therapeutics (PTCT). When did Aduro Biotech IPO? Aduro Biotech (ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. This page (NASDAQ:ADRO) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aduro Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.